We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

65 hedge funds and large institutions have $30.9M invested in Akebia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more call options, than puts

Call options by funds: $466K | Put options by funds: $81K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

0% less capital invested

Capital invested by funds: $30.9M → $30.9M (-$36.1K)

0.2% less ownership

Funds ownership: 28.41% → 28.21% (-0.2%)

13% less funds holding

Funds holding: 75 → 65 (-10)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
65
Holders Change
-10
Holders Change %
-13.33%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
15
Reduced
15
Closed
16
Calls
$466K
Puts
$81K
Net Calls
+$385K
Net Calls Change
+$24K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$972K
2
AIM
Alerce Investment Management
Illinois
+$852K
3
Morgan Stanley
Morgan Stanley
New York
+$231K
4
Victory Capital Management
Victory Capital Management
Texas
+$182K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$140K

Top Sellers

Rank Fund Capital Flow
1
OCM
Ovata Capital Management
Hong Kong
-$767K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$623K
3
Renaissance Technologies
Renaissance Technologies
New York
-$418K
4
Jane Street
Jane Street
New York
-$365K
5
Millennium Management
Millennium Management
New York
-$330K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
$4.87K -$646 -846 -9%
AF
52
Advisornet Financial
Minnesota
$2.8K – – –
NA
53
NewEdge Advisors
Louisiana
$1.87K – – –
Fifth Third Bancorp
54
Fifth Third Bancorp
Ohio
$1.85K – – –
BAM
55
Belpointe Asset Management
Nevada
$1.26K – – –
TWC
56
TD Waterhouse Canada
Ontario, Canada
$1.16K – – –
TC
57
Truvestments Capital
Florida
$424 – – –
AF
58
Allworth Financial
California
$420 – – –
Osaic Holdings
59
Osaic Holdings
Arizona
$414 – – –
BWP
60
Baldwin Wealth Partners
Massachusetts
$314 – – –
HCP
61
Hexagon Capital Partners
Arkansas
$104 – – –
FDCDDQ
62
Federation des caisses Desjardins du Quebec
Quebec, Canada
$84 – – –
FWM
63
Focused Wealth Management
New York
$36 – – –
Citigroup
64
Citigroup
New York
$27 -$517 -677 -93%
Two Sigma Investments
65
Two Sigma Investments
New York
– -$216K -374,289 Closed
Invesco
66
Invesco
Georgia
– -$142K -245,507 Closed
Ameriprise
67
Ameriprise
Minnesota
– -$95K -163,400 Closed
Ohio Public Employees Retirement System (OPERS)
68
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$87K -149,945 Closed
E
69
Ergoteles
New York
– -$56.3K -97,521 Closed
Qube Research & Technologies (QRT)
70
Qube Research & Technologies (QRT)
United Kingdom
– -$8.57K -14,855 Closed
Citadel Advisors
71
Citadel Advisors
Florida
– -$10.2K -13,397 Closed
CSS
72
Cubist Systematic Strategies
Connecticut
– -$6.48K -11,232 Closed
UCFA
73
United Capital Financial Advisors
Texas
– -$5.97K -10,299 Closed
OCM
74
Ovata Capital Management
Hong Kong
– -$767K -9,100 Closed
Rockefeller Capital Management
75
Rockefeller Capital Management
New York
– -$2K -3,771 Closed
1 2
3
4

AKBA Hedge Fund Activity: Q1 2023 in Review

65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2023, worth a combined $30.9M — down 0.12% from $30.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AKBA and 8 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Vanguard Group, adding an estimated $972K. The largest seller was Ovata Capital Management, exiting entirely with an estimated $767K sold.

  • 65 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2023, down from 75 in Q4 2022.
  • Funds reported $30.9M of Akebia Therapeutics stock for Q1 2023, down 0.12% quarter-over-quarter.
  • 8 funds opened new Akebia Therapeutics positions in Q1 2023 and 16 closed out, a net change of -8 holders.
  • The largest Akebia Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $972K added.
  • The largest Akebia Therapeutics seller in Q1 2023 was Ovata Capital Management, an estimated $767K sold.

Based on aggregated 13F filings for Q1 2023.